Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains
This article was originally published in The Tan Sheet
Executive Summary
Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27